Kennedy Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Kennedy Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-64,799	Closed	-$3.53M	–	777
2019 Q4	$3.53M	Sell	64,799 -1,306	-2%	-$64.7K	0.09%	429
2019 Q3	$2.76M	Buy	66,105 +47,725	+260%	+$2.02M	0.07%	475
2019 Q2	$805K	Buy	18,380 +1,104	+6%	+$62.2K	0.02%	622
2019 Q1	$889K	Sell	17,276 -17,093	-50%	-$738K	0.02%	623
2018 Q4	$1.27M	Sell	34,369 -44,476	-56%	-$1.6M	0.03%	588
2018 Q3	$2.96M	Buy	+78,845	New	+$2.9M	0.06%	533

Other funds holding BHVN

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Kennedy Capital Management's BHVN Position: Q1 2020 in Review

Kennedy Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2020, closing a stake of 64,799 shares — an estimated $3.53M sold.

Kennedy Capital Management first reported a position in BHVN in Q3 2018 and held it in 6 quarters. The position peaked at $3.53M in Q4 2019. 175 funds tracked by Wall St. Rank hold BHVN as of Q1 2020.

Kennedy Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2020 after selling out during the quarter.
Kennedy Capital Management sold 64,799 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2020, an estimated $3.53M.
Kennedy Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2018 and held it in 6 quarters.
Kennedy Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $3.53M in Q4 2019.
175 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2020.

Based on Kennedy Capital Management's 13F filing for Q1 2020, filed 15 May 2020.